Shire Is Agnostic On Baxalta's Biosimilars Pipeline As Integration Begins
In an interview, CEO Ornskov notes that prioritization of combined company's assets is only just beginning with closing of the $32bn merger.
In an interview, CEO Ornskov notes that prioritization of combined company's assets is only just beginning with closing of the $32bn merger.